Sotera Health CO 8-K filings

Sotera Health Company announced the resignation of Class I director James C. Neary, effective August 13, 2026, with the board size adjusted to eleven directors.

Sotera Health announced robust second-quarter 2026 financial results, exceeding expectations and prompting an upward revision of its full-year 2026 outlook.

Sotera Health Company stockholders elected four Class III directors, approved executive compensation, and ratified its auditor.

Sotera Health Company has amended its First Lien Credit Agreement, reducing interest rate spreads and refinancing term loans.

Sotera Health Company announces the termination of its Stockholders Agreement following a significant share offering by its former private equity sponsors.

Sotera Health announced a CEO transition and reported a strong first quarter of 2026 with significant revenue and Adjusted EBITDA growth, reaffirming its full-year outlook.

Sotera Health Company announced the appointment of Kenneth D. Krause as a Class I director, effective March 16, 2026, following the resignation of Constantine S. Mihas.

Sotera Health's major stockholders are selling 25 million shares at $15.27 each in a secondary offering, with the company receiving no proceeds.

Sotera Health announced robust financial results for 2025, marking its 20th consecutive year of revenue growth, and provided an optimistic outlook for 2026.

Sotera Health Company announced the expansion of its Board of Directors to twelve members and the appointment of former Timken CEO Richard G. Kyle as a new independent Class III director.

Sotera Health Company announced preliminary full-year 2025 revenue exceeding $1.16 billion, marking over two decades of continuous growth.

Sotera Health Company's major stockholders, including affiliates of Warburg Pincus and GTCR, sold 30 million common shares at $15.651 per share in a secondary offering, with the company receiving no proceeds.

Sotera Health Company announced robust third-quarter and year-to-date 2025 financial results, driven by strong revenue and Adjusted EBITDA growth, leading to an increased full-year Adjusted EBITDA and Adjusted EPS outlook.

Sotera Health Company amended its First Lien Credit Agreement, repricing $1.42 billion in term loans and reducing interest rates by 0.50%.

Sotera Health Company's major stockholders, including Warburg Pincus and GTCR affiliates, sold 20 million common shares in a secondary offering, with the company receiving no proceeds.

Sotera Health Company announced robust second-quarter and first-half 2025 financial results, leading to an upward revision of its full-year 2025 outlook for key metrics.

Sotera Health Company's subsidiary, Sterigenics U.S., LLC, has entered a binding term sheet to resolve 129 ethylene oxide claims related to its former Willowbrook, Illinois facility for $34 million.

Sotera Health Company announced that its stockholders overwhelmingly approved all proposals at the 2025 annual meeting, including the election of three Class II directors, advisory approval of executive compensation, and ratification of Ernst & Young LLP as independent auditors.

Sotera Health's first-quarter 2025 results show revenue growth but a net loss due to a settlement related to ethylene oxide (EO) claims.

Sterigenics U.S., LLC, a subsidiary of Sotera Health Company, has agreed to a $30.9 million settlement to resolve 97 ethylene oxide (EO) claims related to its former Willowbrook, Illinois facility.

Sotera Health announces its fourth-quarter and full-year 2024 financial results, showing a 4.9% increase in net revenues for the year and provides its initial 2025 outlook.

Sotera Health expects full-year 2024 revenues of approximately $1.1 billion, representing nearly 5% growth versus 2023.

Sotera Health Company has appointed Vincent K. Petrella as Lead Independent Director, effective January 2, 2025.

Sotera Health held its Investor Day, outlining future growth plans and a long-term financial outlook, while also warning that 2024 Adjusted EBITDA could fall slightly below guidance due to a strengthening US dollar.

Sotera Health announced positive financial results for the third quarter of 2024, with revenue and earnings growth, and reaffirmed its full-year outlook.

Sotera Health Company disclosed a secondary offering of 25 million shares by selling stockholders and the resignation of a board member due to a decrease in GTCR's board designation rights.

Sotera Health announced an 8% increase in second-quarter revenue and reaffirmed its 2024 financial outlook, despite a decrease in net income due to debt refinancing costs.

Sotera Health Company has increased its board size and appointed Christopher A. Simon as a new Class III director, effective August 1, 2024.

Sotera Health successfully refinanced its existing debt by securing a $1.5 billion term loan and issuing $750 million in senior secured notes, both maturing in 2031.

Sotera Health Company's shareholders approved an amendment to the company's charter to limit officer liability and elected four directors at the 2024 Annual Meeting.